Lonza and Agennix have made a tactical alliance over the Phase III production of a non-small cell lung cancer therapy in the hopes it will improve the chance of joint manufacturing after the commerical launch.
Biomira and Antisoma have both released clinical data showing their
respective drugs, a vaccine vs. a standard molecule, improve
anticancer responses and survival for patients with non-small cell
lung cancer (NSCLC).
Helix BioPharma and BioVectra have signed a deal for the
manufacture of Helix's new lung cancer drug for clinical trials - a
move that strengthens the already existing relationship between the
two Canadian firms.
A recent paper has emerged, which details results of a clinical
laboratory test and its ability to accurately predict drug response
in lung cancer. The test gives way to the possibility of less
Researchers in the US have shed light on how tumours acquire
resistance to kinase inhibitors. The discovery may help explain the
acquired resistance observed in chemotherapy, which currently
blights existing cancer treatments.
Hana Biosciences announced today the clinical trial initiation of
PT-523 to evaluate this compound as a single agent in relapsed
non-small cell lung cancer (NSCLC). Lung cancer continues to carry
the poorest prognosis of cancer, with...
Allos Theraputics have initiated a phase 1 study of its
investigational drug PDX (pralatrexate) that has so far proved
effective against non-small cell lung cancer (NSCLC). This
treatment has the potential to surpass Methotrexate...
Researchers from medical charity Cancer Research UK have discovered
a new gene that protects against lung cancer, according to a study
published today in the journal Proceedings of the National Academy